Phase 2 Pancreatic Cancer Trial, Recruiting NCT04084496 Sponsor: Sun Yat-sen University Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 2 Pancreatic Cancer Trial, Recruiting

NCT04084496
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with pancreatic cancer (a specific type called adenocarcinoma) that has been confirmed by laboratory testing and has not spread to distant parts of the body
  • People who have had surgery to fully remove their pancreatic cancer
  • People who have not previously received chemotherapy for this cancer
  • People aged 19 to 79 years old who are willing to use contraception during the trial
  • People who are generally well enough to carry out daily activities with little or no limitation (confirm with trial site for exact fitness level required)
  • People whose blood counts are at healthy enough levels, including white blood cells, platelets, and haemoglobin
  • People whose liver and kidney function test results are within acceptable ranges as determined by the trial team
  • People who are willing and able to follow the trial schedule and requirements
  • People who are able to give written consent to participate

Who may not be able to join:

  • People who are pregnant or breastfeeding
  • People whose cancer has spread to distant parts of the body
  • People who have severe bleeding in the digestive system requiring frequent blood transfusions
  • People who are unwilling to use appropriate contraception during the trial (this applies to all participants, including men)
  • People who have a known allergy to any of the study drugs: Oxaliplatin, Irinotecan, Leucovorin, or 5-Fluorouracil
  • People who have serious uncontrolled illness affecting the lungs, heart, liver, or kidneys
  • People who have had another type of cancer in the past 5 years, with the exception of certain skin cancers or early-stage cervical conditions
  • People who have a mental health condition that would prevent them from giving informed consent
  • People who are currently taking other cancer-fighting medications
  • People who have taken an experimental cancer treatment within the 4 weeks before joining
  • People who are known to be HIV-positive
  • People who have a history of ongoing diarrhea, nausea, or vomiting (confirm with trial site)
  • People who have moderate or severe nerve-related symptoms such as numbness or tingling (confirm with trial site for exact grading)
  • People who have had a serious heart attack within the past 6 months, heart failure, or unstable chest pain
  • People who have an active infection or inflammation causing a body temperature of 38°C or higher

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yuhong Li, Sun Yat-Sen University Cancer Center

Phone: 13760612003

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 September 2019
Est. completion
31 December 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Disease free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov